KYMERA THERAPEUTICS I

Kymera Therapeutics to Participate in Upcoming November Investor Conferences

05 11 2024 04:00:00 提供 Nasdaq GlobeNewswire

Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update

31 10 2024 04:30:00 提供 Nasdaq GlobeNewswire

Kymera Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader, for the Treatment of TH2 Immuno-Inflammatory Diseases

24 10 2024 04:00:00 提供 Nasdaq GlobeNewswire

Kymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31

23 10 2024 04:15:00 提供 Nasdaq GlobeNewswire

Kymera Therapeutics Announces Three Scientific Presentations at the EORTC-NCI-AACR 2024 Symposium

23 10 2024 04:00:00 提供 Nasdaq GlobeNewswire

Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 Degrader

09 10 2024 04:00:00 提供 Nasdaq GlobeNewswire

Kymera Therapeutics Presents Preclinical Data for KT-621, a Potent, Selective, First-In-Class, Oral STAT6 Degrader at the EADV Congress

25 9 2024 04:00:00 提供 Nasdaq GlobeNewswire

Kymera Therapeutics to Participate in Upcoming September Investor Conferences

28 8 2024 04:00:00 提供 Nasdaq GlobeNewswire

Kymera Therapeutics Announces Closing of Upsized $225 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

21 8 2024 08:15:00 提供 Nasdaq GlobeNewswire

Kymera Therapeutics Announces Pricing of $225 Million Public Offering

19 8 2024 19:45:00 提供 Nasdaq GlobeNewswire

Kymera Therapeutics Announces Proposed Public Offering

19 8 2024 13:01:00 提供 Nasdaq GlobeNewswire

Kymera Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update

07 8 2024 04:00:00 提供 Nasdaq GlobeNewswire

Kymera Therapeutics to Report Second Quarter 2024 Financial Results on August 7

31 7 2024 04:00:00 提供 Nasdaq GlobeNewswire

Kymera Therapeutics to Present in Fireside Chat at the UBS Virtual Targeted Protein Degradation Day

09 7 2024 04:00:00 提供 Nasdaq GlobeNewswire

Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy

08 7 2024 13:05:00 提供 Nasdaq GlobeNewswire

Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting

14 6 2024 04:00:00 提供 Nasdaq GlobeNewswire

Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting

01 6 2024 05:00:00 提供 Nasdaq GlobeNewswire

Kymera Therapeutics to Participate in Upcoming June Investor Conferences

29 5 2024 04:00:00 提供 Nasdaq GlobeNewswire

Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting

23 5 2024 14:00:00 提供 Nasdaq GlobeNewswire

Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting

22 5 2024 08:20:00 提供 Nasdaq GlobeNewswire